Get started
Author

Dimitra Dalampira

Observed names: D. Dalampira, Dalampira D
ORCID: 0000-0001-6987-4716
Observed ORCID: 0000-0001-6987-4716
OpenAlex ID: A5062738987
Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab‐based quadruplets: A multicenter study by the Greek myeloma study group
2023 · Eirini Katodritou, Efstathios Kastritis, et al. · American Journal of Hematology · 36
PDF
Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implications
2022 · Efstathios Kastritis, Magdalini Migkou, et al. · American Journal of Hematology · 32
Central nervous system multiple myeloma: A real‐world multi‐institutional study of the Greek Myeloma Study Group
2024 · Eirini Katodritou, Dimitra Dalampira, et al. · American Journal of Hematology · 23
PDF
Genetic and Functional Evidence of Complement Dysregulation in Multiple Myeloma Patients with Carfilzomib-Induced Thrombotic Microangiopathy Compared to Controls
2022 · Eleni Gavriilaki, Dimitra Dalampira, et al. · Journal of Clinical Medicine · 14
PDF
Siltuximab in Idiopathic Multicentric Castleman Disease: Real-World Experience
2024 · Ciprian Jitaru, Argyris Symeonidis, et al. · Journal of Hematology · 9
PDF
Self-reported risk of obstructive sleep apnea syndrome, and awareness about it in the community of 4 insular complexes comprising 41 Greek Islands
2022 · Anastasia Adamou, Athanasios-Stefanos Giannopoulos, et al. · Sleep Science · 8
Characteristics and Survival Outcomes of Solitary Plasmacytomas: A 30‐Year Experience of the Greek Myeloma Study Group on 175 Patients
2025 · Eirini Katodritou, Efstathios Kastritis, et al. · American Journal of Hematology · 7
VCd versus VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)
2024 · Efstathios Kastritis, Meral Beksac, et al. · Clinical Lymphoma Myeloma & Leukemia · 5
Update Analysis of Central Nervous System Multiple Myeloma Prognosis and Survival: A Real-World Multi-Institutional Study of the Greek Myeloma Study Group
2023 · Eirini Katodritou, Dimitra Dalampira, et al. · Blood · 5
Incidence, characteristics and outcome of therapy‐related myeloid neoplasms in women with epithelial ovarian cancer after exposure to poly‐ ADPribose polymerase inhibitors: A cancer center experience
2024 · Evgenia Verrou, Prodromos Koutoukoglou, et al. · International Journal of Cancer · 3
Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study Group
2024 · Ioannis Ntanasis-Stathopoulos, Eirini Katodrytou, et al. · Blood · 3
PDF
Clinical characteristics and outcome of early‐stage diffuse large B cell lymphoma of female genital track: A retrospective study of the Hellenic cooperative lymphoma group
2024 · Evgenia Verrou, Sotirios G. Papageorgiou, et al. · Hematological Oncology · 3
Evaluation of Clinical Characteristics and Prognostic Factors of Early Progressive Disease (EPD) in Newly Diagnosed Multiple Myeloma Patients: Real-World Data of the Greek Myeloma Study Group
2025 · Eirini Katodritou, Efstathios Kastritis, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Disease Characteristics and Treatment Outcomes of Myeloma Patients Under 50 Years of Age: An Analysis of the Balkan Myeloma Study Group
2025 · Despina Fotiou, Sorina Nicoleta Badelita, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
PDF
Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG)
2024 · Efstathios Kastritis, Eirini Katodritou, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2
Bortezomib-Cyclophosphamide-Dexamethasone (VCD) Vs Bortezomib-Lenalidomide-Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma: A Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG)
2023 · Efstathios Kastritis, Meral Beksac, et al. · Blood · 2
P956: Validation of the Second Revision of the International Staging System (r2-iss) for Overall Survival in Multiple Myeloma in a Real World Cohort: an Analysis by the Balkan Myeloma Study Group (bmsg)
2023 · Efstathios Kastritis, Eirini Katodritou, et al. · HemaSphere · 2
Characteristics, Outcome, and Prognostic Factors for Survival and Progression to Multiple Myeloma of Solitary Plasmacytomas: A 30-Year Experience of the Greek Myeloma Study Group
2024 · Eirini Katodritou, Efstathios Kastritis, et al. · Blood · 1
Improved Survival of Patients with Primary Plasma Cell Leukemia with VRD or Daratumumab-Based Quadruplets: A Multicenter Study By the Greek Myeloma Study Group
2022 · Eirini Katodritou, Efstathios Kastritis, et al. · Blood · 1
PA-013 A Real-World Staging System for Multiple Myeloma integrating Age, Performance Status, Renal Function, and the new High-Risk IMS/IMWG System outperforms existing models: a Machine Learning analysis
2026 · Eirini Katodritou, Efstathios Kastritis, et al. · Clinical Lymphoma Myeloma & Leukemia
Myeloma Elderly Prognostic Score ( MEPS ): A Proposed Prognostic Score Integrating Age, Renal Function, Performance Status, and Ultra‐High‐Risk Cytogenetics
2026 · Eirini Katodritou, Bruna Velosa Ferreira, et al. · American Journal of Hematology
Efficacy and Safety of Frontline Alternating Bortezomib-Based Regimens Plus Daratumumab in Primary Plasma Cell Leukemia: Interim Results of Eumeleia Phase 2 Trial by the Greek Myeloma Study Group
2025 · Eirini Katodritou, Sosana Delimpasi, et al. · Clinical Lymphoma Myeloma & Leukemia
Case Report: Sequential lymphomas: may HLA system play a role in this uncommon phenomenon?
2025 · Evgenia Verrou, Ioanna Diamanti, et al. · Frontiers in Oncology
PDF
894 | Real Life Experience With Siltuximab in Castleman Disease
2025 · C. Tomuleasa, C. Jitaru, et al. · Hematological Oncology
PDF
883 | Siltuximab in Idiopathic Multicentric Castleman Disease: Real‐world Experience From Romania and Greece
2025 · C. Tomuleasa, C. Jitaru, et al. · Hematological Oncology
PDF
Works count: 35
Citation count: 160
H-index: 7
I10-index: 4
Year
Topic
Type